Theophylline--an immunomodulatory role in asthma?

Theophylline, a drug used for the treatment of asthma, is recognized as an immunomodulator affecting T-lymphocytes both in vitro and in vivo. The effect of slow-release theophylline (Uniphyllin Continus) on the late asthmatic response (LAR) has been compared with placebo before and after 5 wk of treatment in a double-blind, randomized, parallel group study. Nineteen volunteers with stable mild asthma successfully completed the study. All were dual responders with a documented late response to inhaled house dust mite extract. The LAR was assessed both in terms of changes in lung function and in peripheral blood T-lymphocyte subsets. The mean (SEM) maximal late fall in FEV1 before and after treatment was 28.8 (4.1)% and 7.8 (2.0)% with theophylline, versus 35.8 (5.1)% and 29.1 (5.0)% with placebo (p = 0.046; Cl, 0.3-26.9). Corresponding figures for specific airway conductance (SGaw) were 46.4 (8.4)% and 7.2 (8.0)% with theophylline versus 46.2 (7.2)% and 44.8 (7.7)% with placebo (p = 0.008; Cl, 11.2 to 64.1). This was achieved at a mean (SD) trough serum theophylline level of only 7.8 (3.5) micrograms/ml. Airway responsiveness to methacholine was not significantly changed 24 h after the initial allergen challenge. There was a trend towards a decrease in baseline responsiveness after treatment with theophylline compared with that after placebo (p = 0.07). Studies of peripheral blood lymphocytes showed a modifying effect of treatment on the allergen-induced changes in CD4 and CD8 counts 48 h after challenge. Previous studies have shown a protective effect of theophylline on the LAR at serum theophylline concentrations within the conventional range for bronchodilation.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  N. Barnes,et al.  Trial of cyclosporin in corticosteroid-dependent chronic severe asthma , 1992, The Lancet.

[2]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[3]  B. Undem,et al.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. , 1991, Thorax.

[4]  C. Persson,et al.  Effect of different bronchodilators on airway smooth muscle responsiveness to contractile agents. , 1991, Thorax.

[5]  A. B. Kay.  Lymphocytes in asthma. , 1991, Respiratory medicine.

[6]  M. Schuyler,et al.  Dynamic T-cell changes in peripheral blood and bronchoalveolar lavage after antigen bronchoprovocation in asthmatics. , 1991, The American review of respiratory disease.

[7]  S. Durham.  The significance of late responses in asthma , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  L. Hendeles,et al.  115 Theophylline attenuation of allergen-induced airway hyper-reactivity and late response , 1991 .

[9]  R. Vestal,et al.  Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. , 1990, The Journal of allergy and clinical immunology.

[10]  R. Pabst,et al.  Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? , 1990, Immunology today.

[11]  P. O'Byrne,et al.  Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine. , 1989, The Journal of allergy and clinical immunology.

[12]  H. Chrystyn,et al.  Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times. , 1989, British journal of clinical pharmacology.

[13]  C. Corrigan,et al.  T LYMPHOCYTE ACTIVATION IN ACUTE SEVERE ASTHMA , 1988, The Lancet.

[14]  R. Vestal,et al.  Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3',5'-adenosine monophosphate. , 1988, The American review of respiratory disease.

[15]  O. Cromwell,et al.  Allergen-induced recruitment of bronchoalveolar helper (OKT4) and suppressor (OKT8) T-cells in asthma. Relative increases in OKT8 cells in single early responders compared with those in late-phase responders. , 1987, The American review of respiratory disease.

[16]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[17]  G. Fink,et al.  Theophylline‐induced alterations in cellular immunity in asthmatic patients , 1987, Clinical allergy.

[18]  R. Pauwels,et al.  The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. , 1985, The Journal of allergy and clinical immunology.

[19]  P. Sierra,et al.  T cell subsets in allergic respiratory disease using monoclonal antibodies. , 1984, Annals of allergy.

[20]  A. Campbell,et al.  Changes in T-lymphocyte subpopulations after antigenic bronchial provocation in asthmatics. , 1984, The New England journal of medicine.

[21]  R. Chandra,et al.  NUMERICAL AND FUNCTIONAL DEFICIENCY OF SUPPRESSOR T CELLS PRECEDES DEVELOPMENT OF ATOPIC ECZEMA , 1983, The Lancet.

[22]  E. Gelfand,et al.  Induction and separation of antigen-dependent T helper and T suppressor cells in man , 1978, Nature.

[23]  F. Hargreave,et al.  Bronchial reactivity to inhaled histamine: a method and clinical survey , 1977, Clinical allergy.

[24]  M. Turner‐Warwick.  Study of Theophylline Plasma Levels after Oral Administration of New Theophylline Compounds , 1957, British medical journal.